These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33296539)

  • 21. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
    Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
    Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
    Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
    [No Abstract]   [Full Text] [Related]  

  • 24. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
    Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
    G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Shayesteh Alam M; Papp KA; Desjardins O; Jean C
    J Cutan Med Surg; 2022; 26(4):361-370. PubMed ID: 35322692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
    Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
    J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
    Holcomb ZE; Porter ML; Kimball AB
    Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging drugs for the treatment of hidradenitis suppurativa.
    Folkes AS; Hawatmeh FZ; Wong A; Kerdel FA
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
    Samycia M; Brassard A
    J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
    Amano M; Grant A; Kerdel FA
    Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review.
    Montero-Vilchez T; Pozo-Román T; Sánchez-Velicia L; Vega-Gutiérrez J; Arias-Santiago S; Molina-Leyva A
    J Dermatolog Treat; 2022 Feb; 33(1):348-353. PubMed ID: 32279593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa.
    Gergely LH; Gáspár K; Brodszky V; Kinyó Á; Szegedi A; Remenyik É; Kiss NF; Bató A; Péntek M; Gulácsi L; Sárdy M; Bánvölgyi A; Wikonkál N; Rencz F
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2584-2592. PubMed ID: 32618022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa.
    Williams J; Guzik C; Wadhera A; Naik H
    J Drugs Dermatol; 2023 Jun; 22(6):615-618. PubMed ID: 37276155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
    Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
    Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hidradenitis suppurativa in a prepubertal girl.
    Lopes S; Gomes N; Trindade E; Azevedo F; Magina S
    Acta Dermatovenerol Alp Pannonica Adriat; 2019 Sep; 28(3):139-141. PubMed ID: 31545394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.